These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 10608353

  • 1. Antibody-mediated endocytosis of G250 tumor-associated antigen allows targeted gene transfer to human renal cell carcinoma in vitro.
    Dürrbach A, Angevin E, Poncet P, Rouleau M, Chavanel G, Chapel A, Thierry D, Gorter A, Hirsch R, Charpentier B, Senik A, Hirsch F.
    Cancer Gene Ther; 1999; 6(6):564-71. PubMed ID: 10608353
    [Abstract] [Full Text] [Related]

  • 2. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL, Zisman A, Pantuck A, Calilliw R, Hernandez JM, Paik S, Nguyen D, Gitlitz B, Shintaku PI, de Kernion J, Figlin R, Belldegrun A.
    Cancer Res; 2001 Nov 01; 61(21):7925-33. PubMed ID: 11691814
    [Abstract] [Full Text] [Related]

  • 3. Immunohistochemical analysis of tumor antigen saturation following injection of monoclonal antibody G250.
    Steffens MG, Oosterwijk-Wakka JC, Zegwaart-Hagemeier NE, Boerman OC, Debruyne FM, Corstens FH, Oosterwijk E.
    Anticancer Res; 1999 Nov 01; 19(2A):1197-200. PubMed ID: 10368675
    [Abstract] [Full Text] [Related]

  • 4. Target-specific activation of mast cells by immunoglobulin E reactive with a renal cell carcinoma-associated antigen.
    Luiten RM, Fleuren GJ, Warnaar SO, Litvinov SV.
    Lab Invest; 1996 Feb 01; 74(2):467-75. PubMed ID: 8780164
    [Abstract] [Full Text] [Related]

  • 5. Targeted gene transfer to hepatocellular carcinoma cells in vitro using a novel monoclonal antibody-based gene delivery system.
    Mohr L, Schauer JI, Boutin RH, Moradpour D, Wands JR.
    Hepatology; 1999 Jan 01; 29(1):82-9. PubMed ID: 9862854
    [Abstract] [Full Text] [Related]

  • 6. Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models.
    van Schaijk FG, Oosterwijk E, Molkenboer-Kuenen JD, Soede AC, McBride BJ, Goldenberg DM, Oyen WJ, Corstens FH, Boerman OC.
    J Nucl Med; 2005 Mar 01; 46(3):495-501. PubMed ID: 15750164
    [Abstract] [Full Text] [Related]

  • 7. [Construction of a recombinant adenovirus expression vector for human renal tumor- associated antigen G250 gene with AdMax system].
    Qi H.
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug 01; 28(9):1617-20, 1625. PubMed ID: 18819881
    [Abstract] [Full Text] [Related]

  • 8. Protocol for gene transduction and expansion of human T lymphocytes for clinical immunogene therapy of cancer.
    Lamers CH, Willemsen RA, Luider BA, Debets R, Bolhuis RL.
    Cancer Gene Ther; 2002 Jul 01; 9(7):613-23. PubMed ID: 12082462
    [Abstract] [Full Text] [Related]

  • 9. Functional balance between T cell chimeric receptor density and tumor associated antigen density: CTL mediated cytolysis and lymphokine production.
    Weijtens ME, Hart EH, Bolhuis RL.
    Gene Ther; 2000 Jan 01; 7(1):35-42. PubMed ID: 10680014
    [Abstract] [Full Text] [Related]

  • 10. A bispecific monoclonal antibody directed against both the membrane-bound complement regulator CD55 and the renal tumor-associated antigen G250 enhances C3 deposition and tumor cell lysis by complement.
    Blok VT, Daha MR, Tijsma O, Harris CL, Morgan BP, Fleuren GJ, Gorter A.
    J Immunol; 1998 Apr 01; 160(7):3437-43. PubMed ID: 9531304
    [Abstract] [Full Text] [Related]

  • 11. Reactivities of mouse monoclonal antibody K2.7 to renal cancers in complement dependent cytotoxicity and antibody dependent cell-mediated cytotoxicity.
    Kinouchi T, Bander NH, Kotake T.
    J Urol; 1995 Jul 01; 154(1):288-92. PubMed ID: 7776448
    [Abstract] [Full Text] [Related]

  • 12. [Renal cancer specific antitumor activities of a mouse monoclonal antibody K2.7 to human renal cell carcinoma].
    Kinouchi T, Kotake T.
    Hinyokika Kiyo; 1992 Nov 01; 38(11):1325-31. PubMed ID: 1485589
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Differential susceptibility of renal carcinoma cell lines to tumor suppression by exogenous Fhit expression.
    Werner NS, Siprashvili Z, Fong LY, Marquitan G, Schröder JK, Bardenheuer W, Seeber S, Huebner K, Schütte J, Opalka B.
    Cancer Res; 2000 Jun 01; 60(11):2780-5. PubMed ID: 10850413
    [Abstract] [Full Text] [Related]

  • 20. Monoclonal antibody G250 targeting CA Ⅸ: Binding specificity, internalization and therapeutic effects in a non-renal cancer model.
    Zatovicova M, Jelenska L, Hulikova A, Ditte P, Ditte Z, Csaderova L, Svastova E, Schmalix W, Boettger V, Bevan P, Pastorek J, Pastorekova S.
    Int J Oncol; 2014 Dec 01; 45(6):2455-67. PubMed ID: 25230982
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.